Results 11 to 20 of about 9,325 (168)

Serum procalcitonin improves diagnosis of infectious complications after CRS/HIPEC

World Journal of Surgical Oncology, 2023
Background Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) improve the survival of selected patients with peritoneal metastasis. A major cause of treatment-related morbidity after CRS/HIPEC is infection and sepsis. HIPEC
Lilian Roth, Dilmurodjon Eshmuminov, Linda Russo, Felix Laminger, Friedrich Kober, Sebastian Roka, Kuno Lehmann   +6 more
doaj   +2 more sources

Treatment planning software for HIPEC [PDF]

, 2023
Peritoneal metastases (PM) predominantly originate from primary cancers such as colorectal, ovarian and gastric cancer. Survival rates decrease dramatically when metastases develop in the peritoneal cavity.
Löke, D.R.
core   +8 more sources

Feasibility study of chemotherapeutic efficacy assessment in hyperthermic intraperitoneal chemotherapy (HIPEC)

Discover Medicine
Purpose CRS-HIPEC serves as the primary treatment for peritoneal cancers. Although CRS-HIPEC frequently yields positive outcomes, some patients may experience a swift recurrence of cancer.
Ahmed H. Mekkawy, Md Khalilur Rahman, Mohammad Breakeit, Krishna Pillai, Samina Badar, Javed Akhter, Michelle Dietz, Shoma Barat, Sarah J. Valle, David L. Morris   +9 more
doaj   +2 more sources

HIPEC for ovarian cancer [PDF]

, 2021
Eierstokkanker staat in de top 10 van kankerdiagnoses bij vrouwen wereldwijd. Ongeveer 70-80% van de patiënten met eierstokkanker, heeft deze ziekte in stadium III of IV, waarbij de ziekte is uitgezaaid naar het buikvlies of buiten de buikholte.
Koole, S.N.
core   +5 more sources

HIPEC and recurrent EOC.xls

, 2022
HIPEC and recurrent ...
Dong Yang (14177049)
core   +1 more source

HIPEC-Induced Acute Kidney Injury: A Retrospective Clinical Study and Preclinical Model

, 2021
Background!#!Hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery (CRS) is the treatment of choice for selected patients with peritoneal malignancies.
Eckert, Christoph, Brune, Maik, Hillebrecht, H. Christian, Schneider, Martin, Wagner, Benedikt, Schmidt, Thomas, Liesenfeld, Lukas F., Klose, Johannes, Büchler, Markus W., Hillebrecht, Hans Christian Winand, Martin Schneider, Benedikt Wagner, Lukas F. Liesenfeld, Thomas Schmidt, Johannes Klose, H. Christian Hillebrecht, Markus W. Büchler, Christoph Eckert, Maik Brune   +18 more
core   +1 more source

Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: Single-institution cohort study

Frontiers in Oncology, 2022
To evaluate the additive effects of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval debulking surgery (IDS) in patients with advanced-stage ovarian cancer.
Yong Jae Lee, Ki Eun Seon, Dae Chul Jung, Jung-Yun Lee, Eun Ji Nam, Sang Wun Kim, Sunghoon Kim, Young Tae Kim   +7 more
doaj   +1 more source

The Global End-Diastolic Volume (GEDV) Could Be More Appropiate to Fluid Management Than Central Venous Pressure (CVP) During Closed Hyperthermic Intrabdominal Chemotherapy with CO2 Circulation

Journal of Investigative Surgery, 2018
Background: Closed hyperthermic intraperitoneal chemotherapy (HIPEC) may increase abdominal pressure and effects of hemodynamic changes due to maintenance hyperthermia.
Francisco Javier Redondo, David Padilla, Pedro Villarejo, Victor Baladron, Patricia Faba, Sergio Sánchez, José Ramón Muñoz-Rodríguez, Natalia Bejarano   +7 more
doaj   +1 more source

The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis

Journal of Ovarian Research, 2019
Background and objective Previous studies about the prognostic value of the HIPEC have yielded controversial results. Therefore, this study aims to assess the impact of HIPEC on patients with ovarian cancer.
Guyu Zhang, Yimin Zhu, Chongdong Liu, Guangming Chao, Ran Cui, Zhenyu Zhang   +5 more
doaj   +1 more source

Cytoreductive HIPEC-Combined Surgery in Treatment of Advanced Ovarian Cancer

Креативная хирургия и онкология, 2022
Background. Ovarian cancer ranks 5th in the structure of female oncological mortality in the Russian Federation, with a first-year post-diagnosis rate of almost 35%. In 75% cases, ovarian cancer is diagnosed at stages III—IV.
M. V. Zabelin, A. S. Safonov, N. V. Kuznetsov   +2 more
doaj   +1 more source